Limit Bets on Clinical-Trial Outcomes Being Placed on Prediction Markets

Betting on clinical trial outcomes and regulatory decisions in US prediction markets could intensify financial pressure for misconduct by incentivizing exploitation of interim trial data and participants’ protected health information. Such bets could also bias how investigators grade outcomes and what participants report, and influence trial enrollment.